Data investigation

Sermorelin for Weight Loss: Zero Trials, Real History

Approved once as Geref, for growth hormone deficiency in children. FDA found its discontinuation was not for safety or effectiveness. No published trial has ever tested it for weight loss.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·7 citations

Part of Peptides: what the evidence shows

Sermorelin has a stranger history than most things sold in this market. It was an FDA-approved drug (Geref, from Serono), approved for diagnosing and treating growth hormone deficiency in children. It was discontinued, and FDA formally recorded that the withdrawal was not for safety or effectiveness reasons.[1] Today it is compounded and sold to adults for weight loss, a use it was never approved for and has never been tested for.

A real approval history, a clean withdrawal record and no evidence at all for the thing it is being sold to do make it one of the more confusing products on a telehealth menu. It is also widely sold: 125 of the 556 sellers in this register offer it.

Disclosure. Seven of the fifteen sellers we earn a commission from list sermorelin. This article was written from the FDA record and from PubMed, and its conclusions are what those sources support. Our full policy is at /disclosure.

What the FDA record actually says

Sermorelin on Drugs@FDA, application NDA 019863
FieldRecord
BrandGEREF
SponsorEMD Serono
Active ingredientSermorelin acetate
Marketing statusDiscontinued
Withdrawal reasonFederal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons

That last row is the one that matters. When a drug is pulled from the market because it was unsafe or did not work, it goes onto a list that bars compounders from using it. Sermorelin is expressly not on that list. EMD Serono told FDA in 2008 that it was discontinuing Geref and asked FDA to withdraw the approvals. FDA’s notice records no reason for that decision, commercial or otherwise.[8] Its finding leaves a compounding route open that a substance like BPC-157 does not have. BPC-157 was never put on the 503A bulks list. Since late October 2026 a 503A pharmacy making it has had only temporary cover from HHS, which says it does not intend to take enforcement action against compounding that meets a strict set of conditions.[7]

This is the opposite of what most people assume. Sermorelin’s regulatory footing is better than the rest of the peptide shelf, not worse. Its problem is the complete absence of evidence for the use it is sold for.

What it was actually approved to do

Geref's use was diagnosing and treating growth hormone deficiency in children, specifically idiopathic GH deficiency, where a child's pituitary is not producing enough for normal growth.[2] Sermorelin is a fragment of growth hormone-releasing hormone, and it works upstream: rather than supplying growth hormone, it prompts the pituitary to release more of your own.

That mechanism is real and measurable. Studies from the 1990s established its pharmacokinetics and confirmed it raises growth hormone output.[3][4] What none of that establishes is what happens to an adult's body weight, which is a different question in a different population. How sermorelin compares with two peptides often sold beside it is covered in ipamorelin vs sermorelin and sermorelin vs tesamorelin.

The evidence for weight loss, in full

There is none. We searched PubMed for sermorelin and weight loss: two results, and neither is a weight-loss study. One concerns a GHRH receptor antagonist (a drug that blocks the pathway rather than stimulating it) in cardiopulmonary disease. The other is a 1996 paper on hypothalamic amenorrhea.

We checked that the search itself works before concluding anything from its silence. “Sermorelin obesity” returns 16 results, so the broader literature is there and indexed. This is a real absence rather than a failed query, and the check matters because an empty search result and a real absence look identical if you do not test for it.

Compare that with what sits beside it on the same menus. Semaglutide has STEP-1, 1,961 participants, 68 weeks, published in the New England Journal of Medicine.[5] Tirzepatide has SURMOUNT-1, 2,539 participants.[6] Sermorelin for weight loss has a mechanism story and testimonials. How it ranks against the other peptides sold for weight is in peptides for weight loss.

The argument sellers make, and what is missing from it

  1. “It raises your growth hormone.” True, and measurable. Growth hormone does influence body composition in people who are deficient in it.
  2. “Growth hormone reduces fat and builds lean mass.” Established in growth hormone deficiency. Extending it to adults with normal levels is the step where the evidence stops and the inference begins.
  3. “So it helps you lose weight.” This is the conclusion nobody has tested. A plausible mechanism is a hypothesis, and the history of obesity medicine is largely a history of plausible mechanisms that did not survive a trial.

None of this is a safety argument. Sermorelin has a real safety history in its approved population, and there is no suggestion it is dangerous. The gap is between “does something to a hormone axis” and “produces weight loss in adults”, and only a trial closes that gap.

If a seller is offering it to you

  • Ask what it is being prescribed for. If the answer is weight loss, ask which study supports that, and notice whether you are given a trial or a mechanism.
  • Ask which pharmacy compounds it. The compounding route is legitimate here, so a seller should be able to name the pharmacy without difficulty.
  • Ask what it costs beside the thing that does have trials. If it is bundled with a GLP-1, ask what each component contributes and what each costs.
  • Ask what happens if it does nothing. A twelve-month prepay on an untested add-on is a different proposition from a monthly one.

Sermorelin usually turns up as an extra on a GLP-1 menu. Nu Image Medical, Ascend Vitality and VigorMeds list it beside compounded semaglutide and tirzepatide, as do Vea Health and Mondae. On the pharmacy question, Harmony Wellness Clinic names the four 503A compounders that ship its medication, while Mondae no longer names the pharmacies that fill its prescriptions. Kingsberg Medical, a growth hormone and testosterone clinic, lists its injectable sermorelin as manufacturer compounded and says only that licensed US pharmacies fill its prescriptions. Renew Youth sells it as a nightly injection and publishes no price.

The commitment question plays out differently by seller. Arc-1 sells each GLP-1 dose as a one-time purchase with no subscription attached. LifespanningRx runs its GLP-1 care inside a wider peptide and longevity program, and Garcia Weight Loss, Aesthetics & Hormone Therapy is an in-person Florida clinic that includes a lab panel and provider visits. Rebody Health no longer sells GLP-1 drugs at all; it sells sermorelin on its own, in injection, spray, troche or cream form. Dose charges $119 for one month of sermorelin or $327 for three months, charged once per 3-month cycle. Optimize HP asks $299.99 a month month to month or $199.99 a month on a 3-month plan, plus a 3% service fee. At Lifeforce it is sold only to members, at $160 per shipment every 25 days on top of a $149 monthly membership.

Common questions

Frequently Asked Questions

Not currently. It was approved as Geref (NDA 019863, EMD Serono) for diagnosing and treating growth hormone deficiency in children, and that product is discontinued. There is no current FDA-approved sermorelin product, which is why what you can buy is compounded.
No, and this is on the record rather than a matter of interpretation. Drugs@FDA carries a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. FDA’s notice does not say why the company stopped selling it.
Its position is stronger than most peptides sold online, precisely because of that Federal Register determination. A drug withdrawn for safety or effectiveness goes on a list that bars compounding, and sermorelin is not on it. That said, the specific authority a given pharmacy is compounding under is a fair question to ask the seller directly.
There is no published trial testing that. We searched PubMed and found two results for sermorelin and weight loss, neither of which is a weight-loss study. What exists is a mechanism (it raises your own growth hormone) plus evidence from growth-hormone-deficient populations, which is not the same as evidence in adults with normal levels.
They are not comparable on evidence. Semaglutide and tirzepatide each have phase 3 trials with thousands of participants measuring weight as the primary endpoint. Sermorelin has none for that purpose. They also work on entirely different systems: the growth hormone axis versus incretin receptors.
It is inexpensive to compound, it has a legitimate-sounding approval history, and it sells well as an add-on. 125 of the 556 sellers in this register list it. None of that is evidence that it works for weight loss, and this page exists because the approval history is the part that sounds most convincing and proves least.

References

  1. 1.U.S. Food and Drug Administration Drugs@FDA record for GEREF (sermorelin acetate), NDA 019863 — marketing status and Federal Register determination on withdrawal FDA Drugs@FDA. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
  2. 2.Prakash A, Goa KL Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs. 1999. PMID: 18031173.
  3. 3.Wilton P, Chardet Y, Danielson K, Widlund L Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion Acta Paediatr Suppl. 1993. PMID: 8329825.
  4. 4.Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Transl Androl Urol. 2020. PMID: 32257855.
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  6. 6.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  7. 7.U.S. Department of Health and Human Services HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B), announced October 28, 2026 HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  8. 8.U.S. Food and Drug Administration Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness Federal Register, March 4, 2013. 2013. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm

Sublingual Semaglutide Drops: What the Evidence Shows

No FDA-approved sublingual semaglutide exists and no human absorption study is published. The approved tablet absorbs about 1% to 2% of its dose even with an enhancer. Evidence and seller prices.

8 min read

Is There a Tirzepatide Pill? What Sellers Ship

No tirzepatide pill is FDA-approved: Mounjaro and Zepbound are injections only. We list the sellers offering compounded tablets, drops and lozenges, what they charge, and the approved GLP-1 pills that do exist.

7 min read

Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule

Approved April 1, 2026, as the second GLP-1 tablet for weight management, and the only one taken with or without food. It produced 11.1% weight loss at 72 weeks, below both injectable rivals. The label, the trials and the interactions.

9 min read

Is Zepbound a Semaglutide? Brand Names vs Molecules

No. Zepbound is tirzepatide, the same molecule as Mounjaro. Nine brand names cover five molecules, and knowing which is which decides your price and your coverage.

6 min read

GLP-1 Telehealth Cancellation and Refund Policies

Can you cancel a GLP-1 telehealth plan any time, and do you get a refund? We read the terms of every seller we track: who lets you stop monthly, who locks you in, and who refunds nothing once medication ships.

6 min read

Mounjaro Alternatives: What Costs Less and What You Give Up

Zepbound is the same drug as Mounjaro and costs $299 to $449 a month self-pay against $499. Ozempic, Trulicity, oral semaglutide and generic liraglutide cost less but did less in head-to-head trials. Compounded tirzepatide, SGLT2s and metformin.

11 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

9.0

YourEra

Semaglutide at $99/month, well below the typical price

6.3

SkinnyRx

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →